Specific Title: Director, Division of Clinical Pharmacology and Indiana Institute for Personalized Medicine
Location: IU School of Medicine
Department: IUSM - Medicine - Clinical Pharmacology
Campus: IU School of Medicine Indianapolis
The Indiana University School of Medicine (IUSOM) seeks highly accomplished and motivated applicants for the Chief in the Division of Clinical Pharmacology and Indiana Institute of Personalized Medicine (IIPM) position. The Indiana University Division of Clinical Pharmacology, which was established in 1986, and the IIPM, founded in 2011, currently play a meaningful role in catalyzing translational initiatives across Indiana University in clinical therapeutics. We have established a critical research program within the translational research enterprise of the Indiana University Medical Centers and Indiana University Health system. We develop effective collaborations across medical center as a whole that are directly relevant to clinical pharmacology, translational medicine and therapeutics research. In this position, you will direct and grow active extramurally funded research and training programs. You will not only continue current programmatic missions (e.g., interdisciplinary research, training and clinical activities) but you are also expected to further grow this dynamic Division of the Department of Medicine under its Chair, Dr. Mark Geraci. In addition, through the IIPM, you will further integrate Division activities with personalized medicine research programs throughout Indiana University. Our Mission: 1.To conduct interdisciplinary ground breaking basic, translational and clinical research and discovery designed to improve understanding and predicting therapeutic drug action, therapeutic efficacy and safety in humans and use this information to personalize drug therapy. 2.To advance the science of clinical pharmacology, translational medicine and therapeutics for the benefit of patients and society by training and generating a robust supply of new leaders in the field in academic, pharmaceutical industry, biotechnology and drug regulatory settings. 3.To provide clinical pharmacology expertise to enhance the rational use of medicines across the medical centers at the university and beyond. Research: Our esearch projects are continuously funded by grants sponsored by the National Institutes of Health as well as other federal funding and non-profit sources. Additionally, our faculty members serve as primary investigators and co-investigators on multiple grants. We have a broad portfolio of resources which support the research programs and develop collaborations bridging the basic and clinical sciences. This portfolio includes serving as the lead site for the INGENIOUS project as part of NHGRI’s IGNITE network (UO1) and extensive involvement in the Indiana University Precision Health Initiative genomic medicine pillar. When sources of research funding are considered, the IIPM and Division research efforts are supported by more than $45 million per year. Active areas of research of the Division include: 1.molecular and clinical pharmacogenomics and personalized medicine; 2.adverse drug reactions; 3.drug disposition, metabolite profiling, drug-drug- and drug-herbal interactions; 4.biomarkers of therapeutic outcomes including genomics and epigenomics; 5.drug use in special populations such as pregnancy and the elderly; and 6.quantitative pharmacology. We play a national role in the implementation of pharmacogenomics in real world clinical settings. This includes the advancement of clinical guidelines, the application of novel clinical trial designs and the evaluation and implementation of methods to measure the economic and system impact of pharmacogenomic testing. Currently, our investigators are PIs and Co-Is of the ongoing application of pharmacogenomics in large health care settings called the INGENIOUS project. We are the academic home of the CTSI Disease and Therapeutic Response Modeling Program and our faculty serve as the Director of the Clinical Pharmacology Analytical Core. Our Division has a long history of major leadership roles in a number of large NIH-funded research projects that include: the Consortium for Breast Cancer Pharmacogenetics as part of the NIHPGRN (UO1); the Indiana University Center for Pediatric Pharmacology (U54); and the Obstetric-Fetal Pharmacology Research Units (OPRU) network (U10). Thus, the Division experienced broad expansion in both research and training and achieved international prominence, making contributions that spanned the entire translational spectrum. This is particularly evident in the areas of drug disposition, drug-drug interactions, endocrine therapy of breast cancer, pharmacogenomics and personalized medicine which formed the basis for the creation of the IIPM. The Division and IIPM are ideally located within a dynamic scientific community and environment within the IUSOM. We are centrally located and are equipped with modern lab and offices. The Division's research activities include collaborations that span the entire medical center including Divisions within the Department of Medicine (e.g., cardiology, infectious disease, oncology, and GI), other clinical (Pediatrics, Obstetrics and Gynecology, Nursing, etc.) and basic science departments (Pharmacology, Medical Genetics, Physiology). In addition, the Division collaborates extensively with investigators across the US. Finally, we have history of positive relationships with the pharmaceutical industry, particularly with Eli Lilly and Co, that brings access to talent and novel therapies. Education: The Division serves as the campus catalyst for a broad teaching operation in clinical therapeutics. This includes a fourth year medical student therapeutics course, a set of didactic lectures on different aspects of clinical pharmacology topics year round, a weekly series of personalized medicine lectures, a weekly journal club that is uniquely designed to cover a wide range of subjects relevant to classical and contemporary clinical therapeutics and the implementation of personalized medicine, and frequent presentations on biostatistics and clinical trial design. The Division has a long and distinguished record of excellence in training leaders that significantly evolved over the years. Now, we represent one of the strongest, most comprehensive and cutting-age training programs in clinical pharmacology, translational medicine and therapeutics. The Indiana University Comprehensive Training Program in Clinical Pharmacology funded by NIH/NIGMS is in year 25 and is currently under renewal (submitted in 2017). Our training program crosses multiple disciplines of medicine, pediatrics, obstetrics, pharmacy practice, informatics and modeling and simulation. Additionally our Division coordinates training programs that are run in parallel and alignment with our T32 program including the Postdoctoral Research Training in Pediatric Clinical and Developmental Pharmacology (NICHD T32), the Indiana CTSI Disease and Therapeutic Response Modeling training program, the Purdue graduate students in the translational research track, and the Vera Bradley sponsored Monogrammed Medicine Program. Our trainees include postdoctoral fellows formally supported by these programs as well as graduate students, postdoctoral researchers, visiting scholars and junior faculty representing broad diversity in race, culture, training background and experience. These programs have led to collaborations in a wide range of peer-reviewed research by graduate students, clinical fellows and international scientists, broadening basic and translational research and training. Committed, experienced and diverse investigators, supported by peer-reviewed funding, are assembled from basic and clinical disciplines to provide quality training. The training environment at the Division, Department and IUSOM is excellent and robust institutional support exists for the training programs. Our training initiatives deeply benefit from productive interaction with seasoned clinical pharmacologists from Eli Lilly and Company and this interaction offers important exposure of our fellows to the world of drug development and enrich training opportunities. Clinical: Several IIPM clinical faculty run a clinical pharmacology/personalized medicine clinic which sees patients with complex drug reactions and side effects. We have set up a fully CLIA certified pharmacogenomics laboratory that provides the basis for a consult service available Monday-Friday 9-5 to physicians within IU Health, Eskenazi and other systems that consult us. We see the Clinical Pharmacology consult service as a distinctive regional resource that can serve as an example of destination medicine within the IU Health system. Our faculty and fellows participate in the adult and pediatric precision genomics tumor board designed to advice cancer expertise on treatment plan based on a patient's genomic and non-genomic unique characteristics. If you are interested in maintaining clinical practice, there will be a possibility to do so within the Department of Medicine.
To apply, you must hold an MD, MD/PhD, PharmD, PharmD/PhD, PhD or equivalent terminal degree. Positions are targeted at established investigators at the Associate Professor or full Professor level that are eligible for a tenure track or tenured faculty appointment at the IUSOM. Board certification in Clinical Pharmacology is desired but not a necessary requirement. Applications from candidates conducting basic, translational, clinical research and/or pharmacoepidemiologic studies of clinical outcome research are specifically encouraged. You should be able to show:
a record of your scholarly achievements and extramural funding;
demonstrated administrative and academic leadership abilities, as well as your dedication to research, education and mentoring;
an understanding of the bridging role of clinical pharmacology between basic and clinical research;
your successful leadership in complex organizational environments;
and excellent communication skills to collaborate with trainees, faculty, healthcare teams and administrators.
Desired skills and qualifications include:
building effective collaborations with interdisciplinary medical disciplines;
a national and international reputation in Clinical Pharmacology;
and the development of performance metrics for faculty.
Founded in 1820, Indiana University is the state’s public university system, comprised of two core campuses—IU-Bloomington and IUPUI—and six regional campuses located throughout the state. Combined, the total student population is more than 114,000 undergraduate, graduate and professional school students. IU is one of the largest employers in the state, with over 20,000 faculty and staff. Indiana ...University is an equal employment and affirmative action employer and a provider of ADA services. Diversity and inclusion remains a core commitment to IU’s mission to cultivate an educational environment that supports equal access, participation and representation on all of its campuses and that provides educational and career opportunities for all.